Efficacy News and Research

RSS

Outbreak of Bordetella parapertussis occurred in Southeastern Minnesota in 2014: Study

Study reports that an outbreak of Bordetella parapertussis occurred in 2014 in Southeastern Minnesota, in the months of October through December. This research is presented at ASM's 55th Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC/ICC).

22 Sep 2015

New study calls for new treatments for carbapenem-resistant Enterobacteriaceae infection

Researchers at The Medicines Company presented data from a multi-national cohort that demonstrates the mortality and morbidity, and poor outcomes, associated with current therapies in patients with infections due to carbapenem-resistant Enterobacteriaceae (CRE). The data from this analysis has guided the design of the company’s on-going clinical studies of its Phase 3 compound, CARBAVANCE® (meropenem/RPX7009) and was presented at the Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC) and the International Congress of Chemotherapy and Infection (ICC) joint meeting in San Diego, CA.

22 Sep 2015

Results from phase 3 women-only HIV study show improved safety, efficacy of Stribild drug

Results from the first phase 3 HIV study to enroll only women show improved safety and efficacy of the drug Stribild over multi-pill antiretroviral drug regimens. The research was presented at ASM's 55th Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC/ICC).

21 Sep 2015

Palatin Technologies reports net loss of $12.1 million for fourth quarter 2015

Palatin Technologies, Inc., a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today announced results for its fourth quarter and fiscal year ended June 30, 2015.

21 Sep 2015

BGB324 shows enhanced tumour clearance in mouse carcinoma models

BerGenBio AS, an oncology biopharmaceutical company, has announced new preclinical data on lead compound, BGB324, in combination with immune checkpoint inhibitors, has been presented as a poster at CRI-CIMT-EATI-AACR - The Inaugural International Cancer Immunotherapy Conference: Translating Science into Survival, in New York.

21 Sep 2015

PharmaMar begins phase II 'Basket' trial to evaluate safety, efficacy of PM1183 in advanced solid tumors

PharmaMar announced today the start of a multicenter, international, open-label, exploratory phase II "Basket" trial (NCT02454972) to evaluate the efficacy and safety of the anticancer agent PM1183 (lurbinectedin) in advanced solid tumors.

18 Sep 2015

UCPH, Beckman Coulter Genomics identify effects of cancer on protein signaling networks within human cells

Studies published of early results of the strategic collaboration between Beckman Coulter Genomics and Linding Lab at UCPH.

From Beckman Coulter Life Sciences - Automation and Genomics 18 Sep 2015

Quethera receives seed investment funding to develop gene therapy for glaucoma

Quethera, a gene therapy company developing a treatment for glaucoma that could prevent blindness, has received seed investment funding led by Midven’s Rainbow Seed Fund alongside co-investor Cambridge Enterprise, the commercialisation arm of the University of Cambridge, to continue pre-clinical development of their therapy.

18 Sep 2015

Cancer-causing gene disrupts internal rhythm, metabolic pathways in cancer cells

Myc is a cancer-causing gene responsible for disrupting the normal 24-hour internal rhythm and metabolic pathways in cancer cells, found a team led by researchers from the Perelman School of Medicine at the University of Pennsylvania. Postdoctoral fellow Brian Altman, PhD, and doctoral student Annie Hsieh, MD, both from the lab of senior author Chi Van Dang, MD, PhD, director Abramson Cancer Center, study body clock proteins associated with cancer cells.

18 Sep 2015

Specific biomarker predicts which HER2-negative breast cancer patients respond to targeted therapy

A multicenter team led by Case Western Reserve has demonstrated that brief exposure to a targeted therapy can tell doctors which HER2-negative patients will respond — and which should switch to another kind of treatment.

18 Sep 2015

Tolerability benefits with sunitinib schedule switch

Switching sunitinib treatment from a 4/2 to a modified 2/1 schedule can improve the tolerability profile for patients with metastatic renal cell carcinoma, say researchers.

17 Sep 2015

Pipetting Solutions for Sample Screening

Our research focuses on interleukin 1 and the inflammasome and their role in innate immunity and inflammation.

From INTEGRA Biosciences 16 Sep 2015

AstraZeneca presents safety and efficacy data for ExQW at 51st Annual Meeting of EASD

AstraZeneca today announced new analyses of exenatide once weekly (ExQW) demonstrating a favorable gastrointestinal (GI) tolerability profile, including less frequent upper and lower GI adverse events (AE), compared to shorter-acting glucagon-like peptide-1 receptor agonists (GLP-1RA), exenatide twice daily (ExBID) and liraglutide once daily (LiraQD).

16 Sep 2015

GENFIT develops reliable, non-invasive diagnostic tool for NASH patients

GENFIT, a biopharmaceutical company at the forefront of developing therapeutic and diagnostic solutions in metabolic and inflammatory diseases, that notably affect the liver or the gastrointestinal system, today announces the development of a new reliable and non-invasive diagnostic method, based on the measurement of a novel type of blood biomarker: small non-coding RNA, or miRNA.

16 Sep 2015

Researchers receive NIH grant to test novel drug therapy for Alzheimer's dementia

Johns Hopkins University researchers have received an estimated $7.5 million National Institutes of Health grant to clinically test what would be the first treatment to prevent or delay the onset of Alzheimer's dementia.

16 Sep 2015

Change Healthcare partners with RxREVU to provide customers with prescription decision support

Change Healthcare, a market leader in healthcare consumer engagement and cost and quality transparency, has joined forces with RxREVU to deliver an enhanced medication selection experience to help consumers, payers and providers make more informed decisions about treatment options, especially those pertaining to therapeutic alternatives.

15 Sep 2015

AgeneBio's HOPE4MCI Phase 3 trial receives support from NIH

AgeneBio, a biopharmaceutical company developing innovative therapeutics for unserved patients battling neurodegeneration, announced today that its HOPE4MCI Phase 3 clinical trial has received support from the National Institutes of Health.

15 Sep 2015

Prenatal repair of myelomeningocele reduces need for CSF shunt within 12 months of life, shows MOMS data

Management of Myelomeningocele Study (MOMS) investigators analyzed updated data on the effects of prenatal myelomeningocele closure on the need for placement of a cerebrospinal fluid (CSF) shunt within the first 12 months of life.

15 Sep 2015

Studies show AHA's Life's Simple 7 and Diabetes Shared Care Program reduce lifetime risk of heart failure

One in four middle-aged adults who survive to age 85 will develop heart failure, according to current estimates.

15 Sep 2015

Vomaris signs exclusive global commercial partnership with Metrex for Procellera Antimicrobial Wound Dressings

Vomaris Innovations, Inc. announced today that it has entered into an exclusive global commercial partnership for its microcurrent generating wound care products, Procellera Antimicrobial Wound Dressings, for the Long Term Care market with Metrex, a professional consumables brand within Kavo Kerr Group, which is a member of the Danaher Corporation.

15 Sep 2015

Efficacy News and Research

Outbreak of Bordetella parapertussis occurred in Southeastern Minnesota in 2014: Study

New study calls for new treatments for carbapenem-resistant Enterobacteriaceae infection

Results from phase 3 women-only HIV study show improved safety, efficacy of Stribild drug

Palatin Technologies reports net loss of $12.1 million for fourth quarter 2015

BGB324 shows enhanced tumour clearance in mouse carcinoma models

PharmaMar begins phase II 'Basket' trial to evaluate safety, efficacy of PM1183 in advanced solid tumors

UCPH, Beckman Coulter Genomics identify effects of cancer on protein signaling networks within human cells

Quethera receives seed investment funding to develop gene therapy for glaucoma

Cancer-causing gene disrupts internal rhythm, metabolic pathways in cancer cells

Specific biomarker predicts which HER2-negative breast cancer patients respond to targeted therapy

Tolerability benefits with sunitinib schedule switch

Pipetting Solutions for Sample Screening

AstraZeneca presents safety and efficacy data for ExQW at 51st Annual Meeting of EASD

GENFIT develops reliable, non-invasive diagnostic tool for NASH patients

Researchers receive NIH grant to test novel drug therapy for Alzheimer's dementia

Change Healthcare partners with RxREVU to provide customers with prescription decision support

AgeneBio's HOPE4MCI Phase 3 trial receives support from NIH

Prenatal repair of myelomeningocele reduces need for CSF shunt within 12 months of life, shows MOMS data

Studies show AHA's Life's Simple 7 and Diabetes Shared Care Program reduce lifetime risk of heart failure

Vomaris signs exclusive global commercial partnership with Metrex for Procellera Antimicrobial Wound Dressings

Industry Focus eBook - Analytical Chemistry (2nd Edition) eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News